Clinical Trial Update: A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ADR-001 in patients with severe pneumonia due to SARS-CoV-2 (COVID-19) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• ADR-001

Snippet

Sponsor: Rohto Pharmaceutical Co., Ltd. | Conditions: SARS-CoV-2 Infection( COVID-19 ) | Phase 2 | Status: COMPLETED